PsychoGenics secures license for ENT1 inhibitor RO7117997 from Roche
PGI Drug Discovery LLC (PsychoGenics), recognized for its phenotypic drug discovery platform, has announced an exclusive license agreement with Roche. This agreement grants PsychoGenics global rights to develop, manufacture, and commercialize RO7117997, an Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor, which is IND-ready. A Promising Candidate for Neuropsychiatric Disorders Discovered through a partnership utilizing PsychoGenics’ AI-enabled […]